The association between humoral immunity to unique and conserved epitopes of the Chlamydia trachomatis 60-kDa heat-shock protein (hsp60) and immunity to human hsp60 was examined in 129 women with laparoscopically verified pelvic inflammatory disease. An ELISA was used to detect antichlamydial IgG and IgA antibodies, IgG antibodies to recombinant human hsp60, and antibodies to two synthetic peptides of chlamydial hsp60. Half of the patients had antibodies to human hsp60, which correlated with the presence of antibodies to the chlamydial hsp60 peptide 260 -271 homologous to the human hsp60 (P Å .01). Antibodies to peptide 260 -271 were associated with antichlamydial IgG (P õ .0001) and IgA (P õ .0001). The results suggest that the autoimmune response to human hsp60 can develop following C. trachomatis upper genital tract infection in women, probably as a consequence of an immune response to an epitope of chlamydial hsp60 crossreactive with the human hsp60.
Chlamydia trachomatis causes a number of sexually trans-
infection of the fallopian tubes may lead to an autoimmune response directed against conserved epitopes expressed in the mitted diseases, including cervicitis, pelvic inflammatory disease (PID), urethritis, epididymitis, and lymphogranuloma vehuman hsp60. Antibodies to some epitopes of chlamydial hsp60 also bind to homologous peptide sequences in human hsp60 nereum. Subsequent chronic inflammatory changes and fibrosis may lead to infertility and ectopic pregnancy [1, 2] . Earlier [12 -14] . Tubal occlusion in patients with immunity to conserved hsp60 epitopes may, therefore, be at least partially due studies suggested that two-thirds of the cases of tubal infertility and one-third of the cases of ectopic pregnancy were caused to an autoimmune response to human hsp60 induced in the tubal mucosa [15, 16] . Detection of antibodies to chlamydial by an earlier episode of chlamydial salpingitis [3, 4] .
The persistent (and, if untreated, recurrent) nature of chlahsp60 that also react with human hsp60 might provide a predictive marker for patients at risk for developing tubal damage mydial infections provides an opportunity for chronic stimulation of the host immune system with chlamydial antigens. The after C. trachomatis infections [17] . At present, there is no indication that production of antibody 60-kDa heat-shock protein (hsp60) has been particularly implicated in the induction of Chlamydia-related immunologic damto hsp60 is disease-specific; rather, it is thought to be related to chronicity of inflammation. Antibodies to C. trachomatis age [5] . The chlamydial hsp60, expressed 2 -26 h after infection [6] , is partially homologous with its counterpart GroEL in hsp60 have been demonstrated in 84% of seropositive women with tubal and in 33% with non -tubal factor infertility [3] , in Escherichia coli and with the human hsp60 [7] .
Involvement of the chlamydial hsp60 in the pathogenesis of 31% of women with PID, in 17% of patients with ectopic pregnancy [9] , and in 9% of healthy Chlamydia-seropositive C. trachomatis -associated ectopic pregnancy [8, 9] and tubal infertility [3, 9, 10] has been demonstrated. Those with high controls [3] . The aim of the study was to investigate whether humoral immuantibody titers to chlamydial hsp60 among women with laparoscopically visualized chlamydial PID have significantly more nity to a synthetic peptide corresponding to a B cell epitope of chlamydial hsp60 is associated with the presence of antibodies to severe tubal alterations [11] .
Extensive amino acid sequence homology between chlamydhuman hsp60, by testing sera from women with PID. ial and human hsp60 [5] suggests that a chronic C. trachomatis
Materials and Methods
Study population. The study population consisted of 129 uterine and bilateral adnexal tenderness and had an elevated Known positive and negative samples were always assayed in parallel with the test samples. Sera from 50 women of reproductive C-reactive protein concentration (ú10 g/L). Women with clinical age without known fertility problems and no history of abortions diagnosis of PID underwent laparoscopy. Only sera from patients or genital tract infections were tested as controls for IgG antibody with laparoscopically proven PID were selected for the study.
to human hsp60. [18] and kept at 070ЊC until investigated.
for Macintosh (SAS Institute, Cary, NC) was used.
Detection of antibodies to chlamydial lipopolysaccharide (LPS).
An ELISA used to detect antibodies directed against synthetic glycoconjugate epitopes of chlamydial LPS was done as described
Results
earlier [19] , with modification [20] . Sera were titrated at 2-fold dilutions, from 1:50 to 1:12,800 for detection of IgA (cIgA-LPS) cIgG-LPS and cIgA-LPS antibodies were detected in 75.9% to aa 151-162 and 260-271 in the hsp sequence, were detected by ELISA. Antibodies to peptide 260-271 react with the homologous peptide in human hsp60, demonstrating that this amino acid sequence is conserved between Chlamydia species and humans. In Table 1 . Distribution of IgG (cIgG-LPS) and IgA (cIgA-LPS) antibodies to chlamydial lipopolysaccharide, human hsp60, and antibodcontrast, humoral immunity to peptide 151-162 was unique; antiies to chlamydial hsp60 peptides 151 -162 and 260 -271 in 129 bodies to this epitope were nonreactive with the corresponding women with pelvic inflammatory disease. human hsp60 sequence [14] . Microtiter plates (Maxisorp Immunoplate; Nunc, Roskilde, Denmark) were precoated with 5 mg/mL Antibodies to streptavidin (Sigma, St. Louis), which was allowed to evaporate overnight at room temperature, and then incubated for 1 h at room IgG antibodies to synthetic peptides corresponding to aa or cIgA-LPS antibodies did not more often have antibodies to human hsp60 or chlamydial hsp60 peptide 151 -162. However, 151 -162 and 260 -271 of the chlamydial hsp60 were present in 41 (31.8%) and 51 (39.5%) of the women, respectively. IgG women having cIgG-LPS or cIgA-LPS antibodies had antibodies to chlamydial hsp60 peptide 260 -271 significantly more antibodies to human hsp60 were detected in sera of 73 (56.6%) patients.
often than did those who did not harbor cIgG-LPS or cIgA-LPS antibodies in their sera: 48% versus 13% and 52% versus At the time the blood sample was drawn, 51% of the 129 women harbored C. trachomatis antigen in the cervix or ure-21% (P Å .001).
Women with cIgG-LPS antibodies harbored antibodies to thra. Both cIgG-LPS and cIgA-LPS antibodies were detected more often in patients with genital C. trachomatis infection both chlamydial hsp60 peptides (P Å .03), as well as to both human hsp60 and chlamydial hsp60 peptide 260 -271 (P (P õ .001 for each). The same was true for antibodies to synthetic peptides 151 -162 and 260 -271 (P õ .01 and P Å .001), significantly more often than did women without such antibodies. Antibodies to both human hsp60 and chlamydial õ .001, respectively). However, there was no difference between C. trachomatis -positive and -negative women in the hsp60 peptide 260 -271 were also more often observed in women with than in women without cIgA-LPS antibodies (P rate of antibodies to human hsp60 (table 2) .
The relation between cIgG-LPS and cIgA-LPS antibodies Å .002) (table 3) . Presence of IgG antibodies to chlamydial hsp60 peptide and antibodies to human hsp60 and two chlamydial hsp60 synthetic peptides is shown in table 3. Women with cIgG-LPS 260 -271 correlated with the presence of antibodies to human . Such correlation, however, was not observed in women with antibodies to chlamydial in this study, we did not perform the microimmunofluorescence test, which differentiates antibodies to different chlamydial spehsp60 peptide 151 -162 (P ú .1).
Significantly more women (P ú .00) with than without anticies. It is possible that highly prevalent C. pneumoniae infections might enhance the anti-hsp response in patients with a bodies to chlamydial hsp60 peptide 151 -162 also harbored antibodies to chlamydial hsp60 peptide 260 -271: 76% (31/41) history of C. trachomatis infections. The low prevalence of antibodies to the chlamydial hsp pepversus 23% (20/88). The same was observed in women having antibodies to peptide 260 -271; that is, significantly more of tide 151 -162 compared with antibodies to peptide 260 -271 suggests that the former epitope may be less immunogenic. them also had developed antibodies to chlamydial hsp60 peptide 151 -162 than did those who did not have such antibodies
The lack of a relationship between antibodies to chlamydial LPS and to peptide 151 -162 also supports this. Although anti -(60% [31/51] women with PID, chlamydial hsp60 may be preferentially expressed or that this protein more readily induces an immune There was no correlation between titers of cIgG-LPS nor cIgA-LPS antibodies and OD for synthetic peptides 151 -162 response than does LPS [3, 8, 9] . Prevalence of IgA, but not IgM, antibodies indicated that or 260 -271 or human hsp60 in ELISA (data not shown).
we were dealing with chronic rather than acute infection. Our previous study, conducted on patients with sexually acquired Discussion reactive arthritis, demonstrated that antibodies to chlamydial LPS are more frequently found in patients with recent disease Seventy-six percent of women with laparoscopically diagnosed PID had serologic evidence of chlamydial infections, as [20] . This would explain the lack of association between antibodies to chlamydial hsp60 and LPS in some of the patients. demonstrated by rLPS-ELISA. However this test detects only genus-specific antibodies, and therefore, it is possible that in On the other hand, production of chlamydial hsp60 antibodies may also dominate over antibodies to another antigenic comsome of the patients, antibodies to another chlamydial species, such as Chlamydia pneumoniae, were also detected. We have pound of chlamydiae-major outer membrane protein (MOMP)-which plays a major role in protective immunity previously demonstrated that 61% of the patients with PID and 61% of women with fertility problems had antibodies to against infection. Women with high responses to chlamydial hsp60 but weak responses to MOMP, that is, low antibody titers C. trachomatis. However, 68% and 84% of such patients also harbored antibodies to C. pneumoniae [18] , a common respiraas detected by microimmunofluorescence, are at increased risk of developing PID if repeatedly exposed to C. trachomatis [11] . tory tract pathogen [21] .
hsp60 comprises an extensive group of compounds involved Another possibility is that in women without demonstrable antibodies to chlamydial LPS, the initial hsp60-related immuin the biogenesis of proteins from the time of synthesis until the assembly of multimeric complexes [22] . They are phylogenogen was a microorganism other than C. trachomatis. The high degree of amino acid sequence conservation between minetically conserved and have 60% sequence homology with eukaryotic hsp60, 50% homology with bacterial hsp60, and crobial hsps [17] then may lead to production of antibodies that recognize the hsp60 amino acid sequence also present in 80% homology with C. trachomatis serovars [17] . The presence of this protein may elicit a delayed-type hypersensitivity rechlamydial hsp60. Antibody responses to human hsp60 were observed in 56% sponse [5] . The homology between bacterial and human hsp60 and also the fact that human hsp60 may be increased locally of women with PID, which is in line with findings in C. trachomatis -associated ectopic pregnancy cases [14] . We also found at the site of infection may indicate a role for hsp60 autoimmunity in the immunopathogenicity of chlamydial infections [23] .
that significantly more women having antibodies to chlamydial LPS also had serum antibodies against both the conserved We have demonstrated that sensitization to human hsp60 is associated with humoral immune response to a conserved episynthetic chlamydial hsp60 peptide 260 -271 and human hsp60. Immune recognition of hsp60 may incite an autoimmune tope of the chlamydial hsp60 in patients with PID and serologic evidence of exposure to chlamydiae. This suggests that an reaction through molecular mimicry [25] . Alternatively, antibody responses to chlamydial hsp60 may signal persistent or autoimmune response to human hsp60 may arise as a conse-/ 9d41$$mr06 01-09-98 19:38:12 jinfa UC: J Infect
